Researchers at the University of Oxford have found that AstraZeneca's asthma treatment Pulmicort reduces the need for hospitalization in COVID-19 patients, sparking hope the medication could join a short list of drugs used to treat the virus.
Pulmicort is a budesonide administered by inhalation, commonly used in the long-term treatment of asthma. In the study, half of the 146 participants took 800 micrograms of the medication twice a day while the other half continued their usual care over a 28-day study period. The findings showed that for those receiving the Pulmicort treatment, the risk of requiring hospitalization reduced by 90%.
The study also found that inhaled budesonide given within seven days of the onset of symptoms reduced recovery time.
Despite it being a small study, the results provide hope at a time that countries are scrambling amid rises in cases triggered by mutations of the coronavirus. Mona Bafadhel of the university's Nuffield Department of Medicine said she was, "heartened that a relatively safe, widely available and well studied medicine such as an inhaled steroid could have an impact on the pressures we are experiencing during the pandemic,” according to a statement shared by Bloomberg.
The positive developments are a welcome reprieve for AstraZeneca who last month announced that they would only be able to deliver a quarter of the doses of its COVID-19 vaccine to the European Union, a vaccine that that many countries around the world are questioning the efficacy of, particularly in older people.
Please click to read our informative text prepared pursuant to the Law on the Protection of Personal Data No. 6698 and to get information about the cookies used on our website in accordance with the relevant legislation.
6698 sayılı Kişisel Verilerin Korunması Kanunu uyarınca hazırlanmış aydınlatma metnimizi okumak ve sitemizde ilgili mevzuata uygun olarak kullanılan çerezlerle ilgili bilgi almak için lütfen tıklayınız.